title: The pharmacogenetics research network: from SNP discovery to clinical drug response.
abstract: The NIH Pharmacogenetics Research Network (PGRN) is a collaborative group of investigators with a wide range of research interests, but all attempting to correlate drug response with genetic variation. Several research groups concentrate on drugs used to treat specific medical disorders (asthma, depression, cardiovascular disease, addiction of nicotine, and cancer), whereas others are focused on specific groups of proteins that interact with drugs (membrane transporters and phase II drug-metabolizing enzymes). The diverse scientific information is stored and annotated in a publicly accessible knowledge base, the Pharmacogenetics and Pharmacogenomics Knowledge base (PharmGKB). This report highlights selected achievements and scientific approaches as well as hypotheses about future directions of each of the groups within the PGRN. Seven major topics are included: informatics (PharmGKB), cardiovascular, pulmonary, addiction, cancer, transport, and metabolism.
authors.affiliation: Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco, California, USA. kathy.giacomini@ucsf.edu
authors.forename: K M
authors.initials: KM
authors.lastname: Giacomini
authors.forename: C M
authors.initials: CM
authors.lastname: Brett
authors.forename: R B
authors.initials: RB
authors.lastname: Altman
authors.forename: N L
authors.initials: NL
authors.lastname: Benowitz
authors.forename: M E
authors.initials: ME
authors.lastname: Dolan
authors.forename: D A
authors.initials: DA
authors.lastname: Flockhart
authors.forename: J A
authors.initials: JA
authors.lastname: Johnson
authors.forename: D F
authors.initials: DF
authors.lastname: Hayes
authors.forename: T
authors.initials: T
authors.lastname: Klein
authors.forename: R M
authors.initials: RM
authors.lastname: Krauss
authors.forename: D L
authors.initials: DL
authors.lastname: Kroetz
authors.forename: H L
authors.initials: HL
authors.lastname: McLeod
authors.forename: A T
authors.initials: AT
authors.lastname: Nguyen
authors.forename: M J
authors.initials: MJ
authors.lastname: Ratain
authors.forename: M V
authors.initials: MV
authors.lastname: Relling
authors.forename: V
authors.initials: V
authors.lastname: Reus
authors.forename: D M
authors.initials: DM
authors.lastname: Roden
authors.forename: C A
authors.initials: CA
authors.lastname: Schaefer
authors.forename: A R
authors.initials: AR
authors.lastname: Shuldiner
authors.forename: T
authors.initials: T
authors.lastname: Skaar
authors.forename: K
authors.initials: K
authors.lastname: Tantisira
authors.forename: R F
authors.initials: RF
authors.lastname: Tyndale
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.forename: R M
authors.initials: RM
authors.lastname: Weinshilboum
authors.forename: S T
authors.initials: ST
authors.lastname: Weiss
authors.forename: I
authors.initials: I
authors.lastname: Zineh
mesh_terms: D000818:Animals; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000235:genetics; D002352:Carrier Proteins / Q000187:drug effects / Q000235:genetics; D004358:Drug Therapy; D006801:Humans; D048088:Informatics; D008171:Lung Diseases / Q000188:drug therapy / Q000235:genetics; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics; D004364:Pharmaceutical Preparations / Q000378:metabolism; D010597:Pharmacogenetics; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide; D019966:Substance-Related Disorders / Q000235:genetics / Q000534:rehabilitation
chemical_list: D002317:Cardiovascular Agents; D002352:Carrier Proteins; D004364:Pharmaceutical Preparations; D010975:Platelet Aggregation Inhibitors